Improving diagnostic methods for low HER2 breast cancer and targeted therapy
Next-generation diagnostic approaches for HER2-low breast cancer and trastuzumab deruxtecan therapy
This study is working on a new test to help doctors better identify breast cancer patients with low HER2 levels, so they can choose the best treatment options, especially for those who might benefit from a specific therapy called trastuzumab deruxtecan.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11063782 on NIH RePORTER |
What this research studies
This research focuses on developing advanced diagnostic techniques to better identify patients with low HER2 expression in breast cancer, which is crucial for determining the most effective treatment options. The study aims to create a high-sensitivity HER2 assay that can accurately classify patients, addressing the limitations of outdated methods that often lead to misdiagnosis. By analyzing the spatial patterns of HER2 expression and tumor characteristics, the research seeks to enhance the precision of treatment selection, particularly for those eligible for trastuzumab deruxtecan therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-low or HER2-negative breast cancer who may benefit from targeted therapies.
Not a fit: Patients with HER2-positive breast cancer or those who do not have breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and improved treatment outcomes for patients with HER2-low breast cancer.
How similar studies have performed: Previous research has shown promise in developing advanced diagnostic techniques for breast cancer, indicating potential success for this novel approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Robbins, Charles John — Yale University
- Study coordinator: Robbins, Charles John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.